Nutraceutical Clinical Trial to Evaluate the Effects of Different Blends in Cognitive Functions of Healthy Volunteers
NCT07879703, Not applicable, Completed, Universidad Católica San Antonio de Murcia
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Nutraceutical Clinical Trial to Evaluate the Effects of Different Blends in Cognitive Functions of Healthy Volunteers | ClinicalTrials.gov |
| NCT number | NCT07879703 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 120 participants, actual | ClinicalTrials.gov |
| Lead sponsor | Universidad Católica San Antonio de Murcia | ClinicalTrials.gov |
| Conditions | Cognitive Function, Healthy Volunteers | ClinicalTrials.gov |
| Interventions | Polyphenol-rich fruit and vegetable nutraceutical, Placebo | ClinicalTrials.gov |
| First posted | 2026-10-19 | ClinicalTrials.gov |
| Last updated | 2026-10-19 | ClinicalTrials.gov |
Registered outcomes 5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change in inhibitory control and selective attention measured by the Stroop Test | Baseline to the end of each 16-week intervention period | Inhibitory control and selective attention will be assessed using the Stroop Test. The primary endpoint is the change in Stroop Test performance from baseline to the end of each 16-week intervention period; higher performance indicates better cognitive function according to the scoring method used. | ClinicalTrials.gov |
| Primary | Change in processing speed and cognitive flexibility measured by the Trail Making Test | Baseline to the end of each 16-week intervention period | Processing speed and cognitive flexibility will be assessed using the Trail Making Test. The outcome is the change in completion time from baseline to the end of each 16-week intervention period; shorter completion time indicates better performance. | ClinicalTrials.gov |
| Primary | Change in verbal memory and logical reasoning measured by the Reynolds Intellectual Screening Test | Baseline to the end of each 16-week intervention period | Verbal memory and logical reasoning will be assessed using the Reynolds Intellectual Screening Test. The outcome is the change in test score from baseline to the end of each 16-week intervention period; higher scores indicate better cognitive performance. | ClinicalTrials.gov |
| Secondary | Change in blood brain-derived neurotrophic factor concentration | Baseline to the end of each 16-week intervention period | Blood samples will be analyzed to assess brain-derived neurotrophic factor concentration as a biomarker related to synaptic plasticity and neuroprotection. | ClinicalTrials.gov |
| Secondary | Change in blood cAMP response element-binding protein concentration | Baseline to the end of each 16-week intervention period | Blood samples will be analyzed to assess cAMP response element-binding protein concentration as a biomarker related to synaptic plasticity and neuroprotection. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 40004930 | RESULT | PubMed |
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 3
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Primary outcome | ConductCognition |
| Trail Making Test A | Primary outcome | ConductCognition |
| Trail Making Test B | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)